|
PHARMACOGENOMICS | ||||
Cambridge Healthtech Institute
, Philadelphia, Pennsylvania October 18-19, 2000 |
||||
Pharmacogenomics is providing a new and steadier hand for the doctor's prescription pad. Each week startling information comes to light about unique variations in an individual's genetic makeup and the resulting highly variable responses to drug metabolism, effectiveness, or toxicity. Attention is inevitably drawn to major cytochrome p45o's, but also to less well known loci. Clinical results are nearing the expected critical mass whereby everyone must indeed "wake up and get ready for pharmacogenomics." At a recent Yale pharmacogenomics conference an industry leader prophesied that before the year was out he expected a major pharmaceutical company to be sued for selling a drug, old or new, without proper gene expression monitoring results. This seems a realistic threat. On an optimistic note, it is easy enough to see the day when pharmacogenomics can be regularly employed as a means to forestall or commute some predestined disease or condition, hereby improving living conditions universally. |
||||
Organized by: |
Cambridge Healthtech Institute |
|||
Invited Speakers: |
Dr. François Thomas, GENSET S.A. Dr. Michael Liebman, Roche Bioscience Dr. Kellye Daniels, CuraGen Corporation |
|||
Deadline for Abstracts: |
September 15, 2000 |
|||
Registration: |
Available on-line |
|||
Email for Requests and Registration: | jlaakso@healthtech.com | |||
Posted by: Jennifer Laakso Host: wks217.healthtech.com date: June 29, 2000 16:03:12 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright. |